Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Cumulative data indicate greater tumor response from the addition of IPI (anti-CTLA-4 antibody)...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Volume: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw379.18 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw379.18 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/1123P/2799942 
|
| Author Notes: | M. Sznol, P.F. Ferrucci, D. Hogg, M. Atkins, P. Wolter, M. Guidoboni, C. Lebbe, J. Kirkwood, J. Schachter, G. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, J. Jiang, F.S. Hodi, J. Wolchok |
| Summary: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Cumulative data indicate greater tumor response from the addition of IPI (anti-CTLA-4 antibody) to NIVO (anti-PD-1 antibody) in MEL pts, but with a higher frequency of adverse events (AEs) than observed with either agent alone. The objective of this pooled analysis is to describe the safety profile of NIVO + IPI across MEL studies in which established guidelines for AE management were utilized.Methods: A retrospective safety review was conducted for three phase 1-3 trials in which all MEL pts who received at least 1 dose of the standard regimen, NIVO 1 mg/kg + IPI 3 mg/kg Q3W x 4, then NIVO 3 mg/kg Q2W until disease progression or unacceptable toxicity. Analyses included AEs, select (immune-related) AEs, time to onset and resolution, use... |
|---|---|
| Item Description: | Gesehen am 14.11.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw379.18 |